These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31026023)

  • 21. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
    Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
    Saller JJ; Haider M; Al-Diffalha S; Coppola D
    Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unsupervised and supervised learning with neural network for human transcriptome analysis and cancer diagnosis.
    Yuan B; Yang D; Rothberg BEG; Chang H; Xu T
    Sci Rep; 2020 Nov; 10(1):19106. PubMed ID: 33154423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
    Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
    Ordóñez NG
    Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.
    Penson A; Camacho N; Zheng Y; Varghese AM; Al-Ahmadie H; Razavi P; Chandarlapaty S; Vallejo CE; Vakiani E; Gilewski T; Rosenberg JE; Shady M; Tsui DWY; Reales DN; Abeshouse A; Syed A; Zehir A; Schultz N; Ladanyi M; Solit DB; Klimstra DS; Hyman DM; Taylor BS; Berger MF
    JAMA Oncol; 2020 Jan; 6(1):84-91. PubMed ID: 31725847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
    Ordóñez NG
    Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the diagnosis of malignant pleural mesothelioma: a necropsy-based study of 171 cases (1997-2016).
    Barbieri PG
    Tumori; 2019 Aug; 105(4):361-362. PubMed ID: 30592233
    [No Abstract]   [Full Text] [Related]  

  • 29. DNA Methylation Markers for Pan-Cancer Prediction by Deep Learning.
    Liu B; Liu Y; Pan X; Li M; Yang S; Li SC
    Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31590287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deep Learning-Based Identification of Tissue of Origin for Carcinomas of Unknown Primary Using MicroRNA Expression: Algorithm Development and Validation.
    Raghu A; Raghu A; Wise JF
    JMIR Bioinform Biotechnol; 2024 Jul; 5():e56538. PubMed ID: 39046787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.
    Xu Q; Chen J; Ni S; Tan C; Xu M; Dong L; Yuan L; Wang Q; Du X
    Mod Pathol; 2016 Jun; 29(6):546-56. PubMed ID: 26990976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
    Naso JR; Tsuji S; Churg A
    Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CancerSiamese: one-shot learning for predicting primary and metastatic tumor types unseen during model training.
    Mostavi M; Chiu YC; Chen Y; Huang Y
    BMC Bioinformatics; 2021 May; 22(1):244. PubMed ID: 33980137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep learning-based classification of mesothelioma improves prediction of patient outcome.
    Courtiol P; Maussion C; Moarii M; Pronier E; Pilcer S; Sefta M; Manceron P; Toldo S; Zaslavskiy M; Le Stang N; Girard N; Elemento O; Nicholson AG; Blay JY; Galateau-Sallé F; Wainrib G; Clozel T
    Nat Med; 2019 Oct; 25(10):1519-1525. PubMed ID: 31591589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
    Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
    Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A platform-independent AI tumor lineage and site (ATLAS) classifier.
    Rydzewski NR; Shi Y; Li C; Chrostek MR; Bakhtiar H; Helzer KT; Bootsma ML; Berg TJ; Harari PM; Floberg JM; Blitzer GC; Kosoff D; Taylor AK; Sharifi MN; Yu M; Lang JM; Patel KR; Citrin DE; Sundling KE; Zhao SG
    Commun Biol; 2024 Mar; 7(1):314. PubMed ID: 38480799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma.
    Nakashima Y; Inamura K; Ninomiya H; Okumura S; Mun M; Kirimura S; Kobayashi M; Okubo K; Ishikawa Y
    Lung Cancer; 2020 Oct; 148():20-27. PubMed ID: 32777673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
    Berg KB; Churg A
    Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.